Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China

Fig. 4

Subgroup analysis according to line of systemic treatment. Kaplan–Meier analysis of overall survival (A) and progression-free survival (B) in patients receiving lenvatinib monotreatment. Kaplan–Meier analysis of overall survival (C) and progression-free survival (D) in patients receiving combination treatment

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us